Call for papers - New frontiers in epilepsy: exploring emerging therapies for epilepsy

Guest Editors

Muhammad Liaquat Raza, PhD, Ministry of National Guard Health Affairs,
Saudi Arabia
Nasrollah Moradikor, PhD, International Center for Neuroscience Research, Georgia

Submission Status: Open | Submission Deadline: 2 September 2025

BMC Neuroscience is pleased to present a new Collection on emerging therapies for epilepsy. The title, "New frontiers in epilepsy: exploring emerging therapies for epilepsy," reflects the urgent need for innovative therapeutic strategies to address the significant challenge posed by drug-resistant epilepsy. This Collection aims to consolidate the latest advancements in research and clinical practice focused on novel therapies, including pharmacological innovations, gene therapies, and non-pharmacological interventions, to provide comprehensive insights into new approaches in epilepsy treatment as well as pharmacoresistance.

New Content Item This Collection supports and amplifies research related to SDG 3: Good Health & Well-Being.

Submit to Collection

Meet the Guest Editors

Back to top

Muhammad Liaquat Raza, PhD, Ministry of National Guard Health Affairs, Saudi Arabia

Dr Muhammad Liaquat Raza is a distinguished academician, neuroscientist, corporate trainer, and philanthropist, recognized for his significant contributions to pharmacology, neuroscience, health informatics, mental health, and neuro AI. He earned his doctorate in Medical Neurosciences from Charité University of Berlin, Germany, and completed a postdoctoral fellowship at Lund University, Sweden, where he focused on molecular neurophysiology and the development of novel treatments for CNS diseases. With over 20 years of experience, Dr Raza has published extensively in reputable journals and contributed to numerous book chapters. His active involvement in various research projects and collaborations underscores his commitment to advancing knowledge in his fields. Dr Raza's exemplary work has earned him over 40 international awards, honors, and fellowships, reflecting his impactful contributions to pharmacology and neuroscience. He has held leadership roles as Professor, Head, and Director at various universities, further solidifying his status as a leader in academia and research. Additionally, he serves in editorial roles for top-ranked journals, making significant contributions to the scientific community.

Nasrollah Moradikor, PhD, International Center for Neuroscience Research, Georgia

Dr Nasrollah Moradikor is currently Research Director and Head of Brain Aging and Dementia at the International Center for Neuroscience Research in Georgia. Dr Nasrollah has demonstrated exceptional leadership skills in promoting applied neuroscience research and establishing fruitful collaborations among scientists worldwide. In 2021, Dr Nasrollah founded a new community platform named “Neuroscience Network” to support and develop neuroscience in the world. He has over 15 years of research and teaching experience and until now has chaired many national and international events in the area of neuroscience. Nasrollah has been on the scientific advisory board and evaluation committees of several institutions abroad. He has published more than 100 scientific papers, and he currently serves as an editor, editorial board member, and section editor of several reputed journals in the field of neuroscience. His contributions to the scientific community are evident through his publications, as well as more than 15 years of editorial expertise. He is an active professional member of IBRO, FENS, EBBS, ISN, ESN, and MDS.

About the Collection

BMC Neuroscience is pleased to present a new Collection on emerging therapies for epilepsy. The title, "New frontiers in epilepsy: exploring emerging therapies for epilepsy," reflects the urgent need for innovative therapeutic strategies to address the significant challenge posed by drug-resistant epilepsy (DRE). Despite the availability of numerous antiseizure medications (ASMs), approximately one-third of patients remain refractory to treatment, leading to increased morbidity, reduced quality of life, and a heightened risk of psychosocial issues. This Collection aims to consolidate the latest advancements in research and clinical practice focused on novel therapies, including pharmacological innovations, gene therapies, and non-pharmacological interventions, to provide comprehensive insights into new approaches in epilepsy treatment as well as pharmacoresistance.

The primary aims of this Collection are to highlight recent advancements in the development of next-generation therapies for epilepsy, explore the mechanisms underlying drug resistance and how these insights can inform new treatment strategies, foster discussions on personalized medicine approaches tailored to individual patient needs and genetic profiles, and bring together insights from neurology, pharmacology, genetics, and neuroengineering.

This Collection distinguishes itself from standard epilepsy treatment discussions by specifically focusing on the innovative approaches being developed to address the complexities of DRE. While traditional epilepsy treatments primarily revolve around established ASMs and their combinations, this issue will explore into cutting-edge research that seeks to understand and overcome the limitations of these conventional therapies.

Topics of interest to this Collection include, but are not limited to:

Innovative pharmacological agents: review of new ASMs and their mechanisms of action
Gene and cell therapies: exploration of genetic approaches to modify disease progression
Neurostimulation techniques: efficacy of devices like responsive neurostimulation (RNS) and deep brain stimulation (DBS)
Precision medicine in epilepsy: tailoring treatments based on genetic and phenotypic profiles
Non-pharmacological interventions: the role of diet, lifestyle changes, and complementary therapies
Clinical trials and future directions: overview of ongoing trials and their implications for future therapies
Neuroinflammation and epilepsy: investigating the role of inflammation in drug resistance and potential therapeutic targets

There are currently no articles in this collection.

Submission Guidelines

Back to top

This Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "New frontiers in epilepsy: exploring emerging therapies for epilepsy" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.